📇 Rhumatologue · NIMES CEDEX 9 · (30) · Hospitalier

M JEAN-SEBASTIEN GUILLAMO

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Plateau technique de référence
Centre hospitalier universitaire (CHU) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
23 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
108.4 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 NIMES CEDEX 9 (30)HospitalierRPPS 10001438570

📊 Reconnaissance scientifique : 24/100📝 47 articles publiés🇫🇷 Publications académiques françaises (8)

✨ Génération du profil synthétique IA en cours…

Activité de recherche & publications

Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.

Influence scientifique

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Radiotherapy for glioblastoma in the elderly

The New England journal of medicine · 2007

📚 590 citations🎯 RCR 14.24Top 1% NIH🩺 Clinique

Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011

📚 170 citations🎯 RCR 4.76Top 8% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Purpose The management of glioblastoma multiforme (GBM) in elderly patients with poor performance status is not well established. A trial evaluating the efficacy and safety of temozolomide alone in this population was undertaken. Patients and Methods Patients age 70 years or older with newly diagnosed GBM and postoperative Karnofsky performance score (KPS) less than 70 were eligible for this nonrandomized phase II trial. Treatment consisted of 150 to 200 mg/m 2 /d temozolomide for 5 days every 4 weeks until disease progression. Radiotherapy was not administered. The primary end point was overall survival (OS); secondary end points included progression-free survival (PFS), safety, quality of life, and cognition. Results Seventy patients (median age, 77 years; median KPS, 60) were enrolled between July 2007 and February 2009. Grade 3 to 4 neutropenia and thrombocytopenia occurred in 13% and 14% of patients, respectively. Median PFS was 16 weeks (95% CI, 10 to 20 weeks), and median OS was 25 weeks (95% CI, 19 to 28 weeks), comparing favorably with a 12- to 16-week OS expected from a purely supportive approach. Twenty-three patients (33%) improved their KPS by 10 or more points, and 18 (26%) became capable of self-care (KPS ≥ 70). Overall quality of life and cognition improved over time before disease progression. In the 31 tumors evaluated for O 6 -methylguanine–DNA methyltransferase (MGMT) promoter methylation, a methylated status indicated longer PFS (26 v 11 weeks; P = .03) and OS (31 v 19 weeks; P = .03). Conclusion Temozolomide has an acceptable tolerance in elderly patients with GBM and KPS less than 70. It is associated with improvement of functional status in 33% of patients and appears to increase survival compared with supportive care alone, especially in patients with methylated MGMT promoter.

Mobile phone use and brain tumours in the CERENAT case-control study

Occupational and environmental medicine · 2014

📚 118 citations🎯 RCR 5.67Top 6% NIH

Cookies & analyse de trafic

M JEAN-SEBASTIEN GUILLAMO

Pourquoi vous devez consulter ce praticien

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (23) — classées par pathologie

Transversal12

Gériatrie6

Revue générale4

Essai clinique2

Qualité de vie / PROMs1

Partager cette fiche